UOC
LVTX

UBS O'Connor’s LAVA Therapeutics LVTX Stock Holding History

UBS O'Connor’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,502
Closed -$34K – 615
2023
Q1 		$34K Sell
20,502
-50,770
-71% -$142K ﹤0.01% 551
2022
Q4 		$249K Sell
71,272
-3,728
-5% -$17.1K ﹤0.01% 645
2022
Q3 		$343K Buy
+75,000
New +$206K ﹤0.01% 825

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS O'Connor's LVTX Position: Q2 2023 in Review

UBS O'Connor sold out of LAVA Therapeutics (LVTX) in Q2 2023, closing a stake of 20,502 shares — an estimated $34K sold.

UBS O'Connor first reported a position in LVTX in Q3 2022 and held it in 3 quarters. The position peaked at $343K in Q3 2022. 15 funds tracked by Wall St. Rank hold LVTX as of Q2 2023.

  • UBS O'Connor reported no remaining LAVA Therapeutics position as of Q2 2023 after selling out during the quarter.
  • UBS O'Connor sold 20,502 LAVA Therapeutics shares in Q2 2023, an estimated $34K.
  • UBS O'Connor first reported a position in LAVA Therapeutics in Q3 2022 and held it in 3 quarters.
  • UBS O'Connor's LAVA Therapeutics position peaked at $343K in Q3 2022.
  • 15 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2023.

Based on UBS O'Connor's 13F filing for Q2 2023, filed 14 Aug 2023.